
.~ Set Name side by side		Hit Count	Set Name result set	
DB=USPT; PLUR=YES; OP=ADJ				
<u>L6</u>	L1 same (hodgkin\$)	12	<u>L6</u>	
<u>L5</u>	L1 same (hodkgin\$)	0	<u>L5</u>	
<u>L4</u>	L1 same (hodkgin\$ or 'b-cell\$' or 'b-lymphocyte\$')	17	<u>L4</u>	
<u>L3</u>	L1 same (hodkgin\$ or cd20 or cd40)	9	<u>L3</u>	
<u>L2</u>	L1 same (hodkgin\$ or "b-cell" or "b"-lymphocyte)	17	<u>L2</u>	
<u>L1</u>	(combination or combined or synerg\$) same (antibod\$) same (leukemi\$)	248	<u>L1</u>	

END OF SEARCH HISTORY



Search Results -

Term	Documents
HODGKIN\$	0
HODGKIN	2493
HODGKIND	1
HODGKINDON	1
HODGKIND-ET-AL	1
HODGKINET	1
HODGKING	1
HODGKINIAN	3
HODGKINIS .	1
HODGKINLYMPHOMA	1
HODGKINS	1091
(L1 SAME (HODGKIN\$)).USPT.	12

There are more results than shown above. Click here to view the entire set.

Database:	US Patents Full-Text Database US Pre-Grant Publication Full-Text Database JPO Abstracts Database EPO Abstracts Database Derwent World Patents Index IBM Technical Disclosure Bulletins
Search:	L6 Refine Search Recell Text ← Clear
	Search History

DATE: Sunday, June 29, 2003 Printable Copy Create Case

End of Result Set

Generate Collection

L6: Entry 12 of 12

File: USPT

Nov 11, 1997

DOCUMENT-IDENTIFIER: US 5686072 A

TITLE: Epitope-specific monoclonal antibodies and immunotoxins and uses thereof

Brief Summary Text (31):

The present invention has direct utility in the clinical treatment of various human diseases and disorders in which B cells play a role. In particular, it provides effective methods and compositions to delete neoplastic B cells, such as in anti-tumor therapy to treat leukemia or non-Hodgkin's lymphoma. Appropriate therapeutic regimens for using the present antibodies or combination of antibodies and immunotoxins will be known to those of skill in the art in light of the present disclosure. For example, methods using a single immunotoxin, such as described by Vitetta et al., Cancer Res., 51:4052, 1991, incorporated herein by reference, may be straightforwardly adapted for use in accordance herewith by substituting the single immunotoxin with the combination of immunotoxins of the present invention.

Detailed Description Text (15):

The combinations of immunotoxins disclosed herein, and cell cycle arrest-inducing anti-CD19 antibodies in accordance with the invention, are proposed to be of use in the clinical treatment of various human diseases and disorders in which B cells play a role. In particular, they may be used in anti-tumor therapy to treat, for example, patients with leukemia or non-Hodgkin's lymphoma. Methods of immunotoxin treatment using a single immunotoxin have been described in the art, for example, see Vitetta et al., Cancer Res., 51:4052, 1991, incorporated herein by reference. It is contemplated that such methods may be adapted for use in accordance with the present invention by substituting the single immunotoxin of the prior art for the advantageous combination, or the anti-CD19 component, disclosed herein.